New trial aims to stop stomach bleeding before it starts

NCT ID NCT07168395

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether treating enlarged stomach veins (gastric varices) early with a procedure called retrograde transvenous obliteration (RTO) can prevent dangerous bleeding. 68 adults with cirrhosis and gastric varices will be randomly assigned to either RTO or standard care with beta-blocker medication. Researchers will track bleeding episodes, survival, and complications over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Retrograde transvenous obliteration (RTO) procedure

What this could lead to

If successful, this could offer a way to prevent dangerous stomach variceal bleeding before it starts, potentially reducing emergency treatments and improving survival.

What could go wrong

This is a small, early-phase trial with only 68 participants. The procedure carries risks like bleeding or liver complications, and it may not prove better than current medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC VARICES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal varices Hemorrhage hepatic encephalopathy varicose disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••